New Phase III Trial Results for Rivaroxaban Presented at the 49th Annual Meeting of the American Society of Hematology (ASH)

December 8 - 11, 2007
Atlanta, Georgia, USA

Findings from three phase III clinical trials have been presented at the American Society of Hematology (ASH) Annual Meeting. The studies evaluated rivaroxaban in head-to-head comparison with enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery. The presentations highlight results from the recently-completed RECORD1 and RECORD2 studies in total hip replacement surgery as well as additional data from the RECORD3 trial, which evaluated rivaroxaban in total knee replacement surgery.


Tuesday December 11, 2007:
Investor Conference Call - Review of Rivaroxaban Data presented at the 49th ASH Annual Meeting

MP3 audio recording (presentation and discussion)

Transcript (Introduction)Download ( PDF, 61 KB ) collect
Background Information
About Rivaroxaban
Download ( PDF, 67 KB ) collect
About Rivaroxaban Clinical Studies
Download ( PDF, 63 KB ) collect
About RECORD StudiesDownload ( PDF, 59 KB ) collect
Understanding Blood Clotting and Anticoagulant Therapy
Download ( PDF, 105 KB ) collect
Understanding Venous Blood Clots
Download ( PDF, 66 KB ) collect
Glossary
Download ( PDF, 46 KB ) collect



ASH 2007 Abstracts on Rivaroxaban

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial (abstract #6)

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial (abstract #307).

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial (abstract #308)

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study (abstract #1874)

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT) (abstract #1880)

Rivaroxaban Has Protective Effects in a Model of Disseminated Intravascular Coagulation (DIC) in Rats (abstract #935)

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - Prevents Arterial Thrombotic Occlusion in Electrolytically Injured Rat Carotid Arteries (abstract #4003)

Thromboplastin Composition Affects the Sensitivity of Prothrombin Time (PT) Clotting Tests To Direct Factor Xa Inhibitors (abstract #928)

Last updated: January 08, 2014 Copyright © Bayer AG